HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Gilead Intelligence Report

Intelligence report

Intelligence Report · ~12 min read

Gilead Intelligence Report

Generated from 9 signals · 3 evidence sources

Type

Company Intelligence Report

Generated

Aug 1, 2026

Confidence

Moderate Confidence · 73%

Evidence

45 items

Sources

19

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Gilead maintains an active intelligence profile across Endocrinology, Type 2 Diabetes Mellitus, Infectious Disease, HIV, Hepatology. 9 signals are linked with 1 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 73% across 3 tracked sources. Highest-priority development: IND Application Reporting: IND Safety Reports. Regulatory precedent. Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Gilead.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. investigateJun 16, 2026

    Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir

    Infectious Disease · HIV · opportunity score 62

    View detail
  2. regulatory

    IND Application Reporting: IND Safety Reports

    Regulatory precedent may inform portfolio positioning

    View detail
  3. regulatory

    Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug

    Regulatory precedent may inform portfolio positioning

    View detail
  4. regulatory

    Clinical trials for medicines: collection, verification and reporting of safety events

    Regulatory precedent may inform portfolio positioning

    View detail
  5. regulatory

    Drug Trials Snapshots: YARTEMLEA

    Regulatory precedent may inform portfolio positioning

    View detail
  6. regulatory

    Clinical trials for medicines: collection, verification and reporting of safety events

    Regulatory precedent may inform portfolio positioning

    View detail
  7. regulatory

    Clinical trials for medicines: Clinical Trials Regulations transitional arrangements

    Regulatory precedent may inform portfolio positioning

    View detail
  8. regulatory

    Guidance: Clinical trials for medicines: roles and responsibilities

    Regulatory precedent may inform portfolio positioning

    View detail
  9. regulatory

    Clinical trials for medicines: ending a clinical trial

    Regulatory precedent may inform portfolio positioning

    View detail
  10. regulatory

    FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

    Regulatory precedent may inform portfolio positioning

    View detail
  11. regulatory

    FDA Approves First Generic of Priftin (rifapentine) Tablets

    Regulatory precedent may inform portfolio positioning

    View detail
  12. regulatory

    FDA Approves First Generics of Gilotrif (afatinib) Tablets

    Regulatory precedent may inform portfolio positioning

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 487 with buyer quality 10 (Enterprise). Competitive pressure: Low. Portfolio impact: High. 1 investigate-priority signal warrant near-term portfolio review.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • IND Application Reporting: IND Safety Reports

    Moderate Confidence · 83%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Submitting Clinical Trial Datasets to Evaluate the Impact of Immunogenicity on the Pharmacokinetics of Drug

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Clinical trials for medicines: collection, verification and reporting of safety events

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Drug Trials Snapshots: YARTEMLEA

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Clinical trials for medicines: collection, verification and reporting of safety events

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Clinical trials for medicines: Clinical Trials Regulations transitional arrangements

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Guidance: Clinical trials for medicines: roles and responsibilities

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • Clinical trials for medicines: ending a clinical trial

    Moderate Confidence · 72%

    Regulatory precedent may inform portfolio positioning

    Source: MHRA, MHRA, Regunera

    View evidence

  • FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Approves First Generic of Priftin (rifapentine) Tablets

    High Confidence · 95%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA Approves First Generics of Gilotrif (afatinib) Tablets

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • FDA-TRACK: Prescription Drug User Fee Act Review Goals Summary

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Zydus Lifesciences Limited - 722576 - 06/02/2026

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

  • Umendra Life Sciences Private Limited - 721752 - 06/02/2026

    Moderate Confidence · 66%

    Regulatory precedent may inform portfolio positioning

    Source: FDA, FDA, Regunera

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir

    Infectious Disease · HIV

  • FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy)

    Oncology · Antibody-Drug Conjugate

  • FDA Approves KEYTRUDA and Trodelvy Combination for First-Line TNBC Treatment

    Oncology · Triple-Negative Breast Cancer

  • Islatravir and Lenacapavir Show Sustained Virologic Suppression in Phase 3 HIV Trials

    Infectious Disease · HIV

  • FDA Grants Priority Review for BLA761468 (HEPCLUDEX) by Gilead Sciences

    Hepatology · Antiviral

  • FDA Approves Supplement for Biktarvy by Gilead Sciences

    Infectious Disease · HIV

  • FDA Approves Supplemental Application for Trodelvy (Sacituzumab Govitecan-Hziy)

    Oncology · Antibody-Drug Conjugate

  • Gilead's GS-4571 Study Targets Safety and Pharmacokinetics in T2DM and Obesity

    Endocrinology · Type 2 Diabetes Mellitus

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.